Understanding ANKRD11: A Potential Drug and Biomarker (G29123)

Target Name: ANKRD11

NCBI ID: G29123

ANKRD11

Understanding ANKRD11: A Potential Drug and Biomarker

ANKRD11 (also known as LZ16) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the ANKRD family, which includes several related proteins that play important roles in cell signaling and metabolism. One of the unique features of ANKRD11 is its ability to interact with several different signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. This makes it an attractive target for drug development, as it is possible to intervene in these pathways to treat a wide range of diseases.

The TGF-β pathway is a key regulator of cell growth, differentiation, and survival, and is involved in many important processes in the body, including the development and maintenance of tissues and organs, as well as the regulation of cell proliferation and differentiation. ANKRD11 is known to play a role in the TGF-β pathway by regulating the activity of the transcription factor SMAD, which is a key player in the pathway.

The PI3K/Akt pathway is a signaling pathway that is involved in the regulation of cell survival and metabolism, and is activated in response to the presence of certain signaling molecules, such as insulin. ANKRD11 is known to interact with the PI3K/Akt pathway by regulating the activity of the protein Pyknot, which is involved in the PI3K/Akt pathway.

The regulation of ANKRD11 by these signaling pathways makes it an attractive target for drug development. By inhibiting the activity of ANKRD11, it is possible to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, because ANKRD11 is involved in multiple signaling pathways, it is possible to target it with drugs that act in multiple ways, which can improve the effectiveness of the treatments.

In addition to its potential as a drug target, ANKRD11 is also a potential biomarker for several diseases. Its expression is known to be elevated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, because ANKRD11 is involved in the regulation of cell signaling, it is possible to use it as a biomarker for the effectiveness of a treatment. For example, if an treatment is able to inhibit the activity of ANKRD11, it is possible that the treatment will be more effective at reducing the symptoms of the disease.

In conclusion, ANKRD11 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of several important signaling pathways. Its ability to interact with multiple signaling pathways makes it an attractive target for drug development, and its potential as a biomarker for diseases makes it a valuable tool for the diagnosis and treatment of a wide range of conditions. Further research is needed to fully understand the role of ANKRD11 in cell signaling and its potential as a drug and biomarker.

Protein Name: Ankyrin Repeat Domain Containing 11

Functions: Chromatin regulator which modulates histone acetylation and gene expression in neural precursor cells (By similarity). May recruit histone deacetylases (HDACs) to the p160 coactivators/nuclear receptor complex to inhibit ligand-dependent transactivation (PubMed:15184363). Has a role in proliferation and development of cortical neural precursors (PubMed:25556659). May also regulate bone homeostasis (By similarity)

The "ANKRD11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets